Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028GlobeNewsWire • 08/04/20
Emergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured NotesGlobeNewsWire • 08/04/20
Emergent BioSolutions, Inc. (EBS) CEO Bob Kramer on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/31/20
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 GuidanceGlobeNewsWire • 07/30/20
Emergent BioSolutions Triples Its Coronavirus-Vaccine Manufacturing Contract With AstraZenecaThe Motley Fool • 07/27/20
Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine CandidateGlobeNewsWire • 07/27/20
Is Emergent Biosolutions (EBS) a Solid Growth Stock? 3 Reasons to Think " Yes "Zacks Investment Research • 07/21/20
Emergent BioSolutions Set to Join S&P MidCap 400; First Hawaiian to Join S&P SmallCap 600PRNewsWire • 07/20/20
Here's Why Emergent Biosolutions (EBS) is a Great Momentum Stock to BuyZacks Investment Research • 07/20/20
Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020GlobeNewsWire • 07/16/20
Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine DealsZacks Investment Research • 07/09/20
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense FundingGlobeNewsWire • 07/08/20
Will Emergent BioSolutions' Shares March Higher, Can It Continue?Zacks Investment Research • 07/07/20
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate GlobeNewsWire • 07/06/20